Literature DB >> 25158927

Is it more cost-effective for patients with chronic hepatitis b to have a trial of interferon before considering Nucleos(t)ide analogue therapy?

Monica A Konerman1, Anna S Lok1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25158927      PMCID： PMC4339670          DOI： 10.1016/j.cgh.2014.08.024

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN： 1542-3565            Impact factor:   11.382


× No keyword cloud information.
  13 in total

1.  Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C.

Authors:  Y-F Liaw; J-D Jia; H L Y Chan; K H Han; T Tanwandee; W L Chuang; D M Tan; X Y Chen; E Gane; T Piratvisuth; L Chen; Q Xie; J J Y Sung; C Wat; C Bernaards; Y Cui; P Marcellin
Journal:  Hepatology       Date:  2011-11       Impact factor: 17.425

Review 2.  Long-term outcomes in hepatitis B: the REVEAL-HBV study.

Authors:  Chien-Jen Chen; Uchenna H Iloeje; Hwai-I Yang
Journal:  Clin Liver Dis       Date:  2007-11       Impact factor: 6.126

3.  Further analysis is required to identify an early stopping rule for peginterferon therapy that is valid for all hepatitis B e antigen-positive patients.

Authors:  Teerha Piratvisuth; Patrick Marcellin
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

4.  Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a.

Authors:  Vincent Rijckborst; Bettina E Hansen; Peter Ferenci; Maurizia R Brunetto; Fehmi Tabak; Yilmaz Cakaloglu; A Galeota Lanza; Vincenzo Messina; Claudio Iannacone; Benedetta Massetto; Loredana Regep; Massimo Colombo; Harry L A Janssen; Pietro Lampertico
Journal:  J Hepatol       Date:  2012-01-13       Impact factor: 25.083

5.  Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.

Authors:  C-Y Peng; H-C Lai; Y-F Li; W-P Su; P-H Chuang; J-T Kao
Journal:  Aliment Pharmacol Ther       Date:  2012-01-08       Impact factor: 8.171

6.  Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.

Authors:  Sergio Iannazzo; Barbara Coco; Maurizia R Brunetto; Francesca Rossetti; Antonietta Caputo; Andrea Latour; Belen Espinos; Ferruccio Bonino
Journal:  Antivir Ther       Date:  2013-03-13

7.  Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels.

Authors:  Milan J Sonneveld; Bettina E Hansen; Teerha Piratvisuth; Ji-Dong Jia; Stefan Zeuzem; Edward Gane; Yun-Fan Liaw; Qing Xie; E Jenny Heathcote; Henry L-Y Chan; Harry L A Janssen
Journal:  Hepatology       Date:  2013-07-29       Impact factor: 17.425

8.  Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients.

Authors:  Rami Moucari; Vincent Mackiewicz; Olivier Lada; Marie-Pierre Ripault; Corinne Castelnau; Michelle Martinot-Peignoux; Agnes Dauvergne; Tarik Asselah; Nathalie Boyer; Pierre Bedossa; Dominique Valla; Michel Vidaud; Marie-Hélène Nicolas-Chanoine; Patrick Marcellin
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

Review 9.  Management of hepatitis B: our practice and how it relates to the guidelines.

Authors:  Suna Yapali; Nizar Talaat; Anna S Lok
Journal:  Clin Gastroenterol Hepatol       Date:  2013-05-06       Impact factor: 11.382

10.  Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients.

Authors:  Patrick Marcellin; Ferruccio Bonino; Cihan Yurdaydin; Stephanos Hadziyannis; Rami Moucari; Hans-Peter Kapprell; Vivien Rothe; Matei Popescu; Maurizia R Brunetto
Journal:  Hepatol Int       Date:  2012-03-23       Impact factor: 6.047
View more
  1 in total

Review 1.  Personalized treatment of hepatitis B.

Authors:  Anna S Lok
Journal:  Clin Mol Hepatol       Date:  2015-03-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.